- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Thomas Graf Discusses the Effect of Novel Therapies on Private Coverage
Thomas Graf, MD, chief medical officer and vice president, Horizon Blue Cross Blue Shield of New Jersey, discusses the impact of new therapies on private insurance coverage for cancer patients.
Thomas Graf, MD, chief medical officer and vice president, Horizon Blue Cross Blue Shield of New Jersey, discusses the impact of new therapies on private insurance coverage for cancer patients.
Transcript
Will novel therapies have an effect on private coverage?
It’s going to drive cost in a way that’s not been seen. I mean, we’ve seen some explosion in pharmacy costs now exceeding often the physician costs for health insurers. That’s gonna leap another factor here, is that the drug costs continue to escalate as new therapies continue to be produced for more and more patients. The potential number of patients that are eligible for some of the drugs that are available is quite small. The newer drugs will have much wider approachable patient panels. So, the ability to impact total cost for insurers, for employers, for the federal government is dramatic. So, I think some employers will thereby not be able to offer coverage because it will become so expensive to their employees which will drive them to different markets. Clearly, there’s a reduction in the insurance mandate. So, I suspect a lot of patients will go from having private coverage to not having private coverage and then we’re going to have a real issue because access to those drugs will be very restricted in that group.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
